Study aid only. Verify against current guidelines before clinical use.
Board-Prep Notes

Disease-site reference notes for boards review.

Antiphospholipid Syndrome (APS/APLS)

Benign Hematology
Antiphospholipid Syndrome

Definition

Equation-style diagram: at least one clinical criterion (thrombosis or pregnancy morbidity) plus at least one laboratory criterion (lupus anticoagulant, anticardiolipin, anti-beta2GPI) positive twice at least 12 weeks apart equals antiphospholipid syndrome, with a 2023 ACR/EULAR summary.
APS diagnosis: clinical event plus persistent aPL (revised Sapporo/Sydney; 2023 ACR/EULAR). Tap to enlarge.
  • Antiphospholipid syndrome (APS/APLS) is an acquired systemic autoimmune disease defined by vascular thrombosis and/or pregnancy loss or morbidity together with persistently positive antiphospholipid antibodies (aPL).
  • You need a clinical event (arterial, venous, or small-vessel thrombosis, or qualifying obstetric morbidity) PLUS persistent aPL to diagnose APS. aPL alone is not APS.

Revised Sapporo (Sydney) classification: I. Laboratory criteria

  • Only 1 of 3 has to be positive, on TWO occasions ≥12 weeks apart.
  • Lupus anticoagulant (LA) = lupus inhibitor = phospholipid-dependent inhibitor, prolongs PTT by inhibiting conversion of X to Xa and II to IIa. See assay panel below.
  • Anticardiolipin Ab (aCL) IgG and/or IgM: Sapporo cutoff >40 GPL or MPL units, or >99th percentile of your lab.
  • Anti-β2-glycoprotein I (anti-β2GPI) IgG and/or IgM: Sapporo cutoff >99th percentile.
  • Only one positive is enough to say aPL is present.
  • Repeat in ≥12 weeks; if still positive, aPL is confirmed.
  • False positives possible with acute illness and anticoagulation.
  • Other antibodies (antiphosphatidylserine, antiphosphatidylcholine, antiphosphatidylethanolamine) are not established risk factors for thrombosis. Anti-phosphatidylserine may play a role in pregnancy complications. IgA is not part of the criteria.

Lupus anticoagulant assay panel and mixing-study logic

  • A prolonged PTT that fails to correct on a 1:1 mix with normal plasma suggests an inhibitor; a phospholipid-dependent inhibitor (LA) is then confirmed by demonstrating phospholipid dependence (correction when excess phospholipid is added).
Lupus anticoagulant assays
AssayStepsNormal cutoffWorked example (positive)
LA-PTTLA-PTT. Screen: patient plasma with low-phospholipid LA-sensitive aPTT reagent. Mix: patient plus normal plasma (inhibitor fails to correct). Confirm: add excess phospholipid (shortening shows phospholipid dependence).Difference should be <7.9 seconds.Screen without phospholipid 110 sec and confirm with phospholipid 75 sec; 110 minus 75 = 35 (>7.9).
DRVVTRussell viper venom directly activates X to Xa; the phospholipid-dependent Xa-Va complex then converts II to IIa, and thrombin converts I to Ia (FVIII/FIX bypassed). DRVVT screen (patient plasma with low-phospholipid reagent; mix with normal plasma if prolonged); if prolonged, DRVVT confirm (repeat with excess phospholipid; shortening shows phospholipid dependence).Ratio (screen without excess phospholipid divided by confirm with excess phospholipid) should be <1.15.DRVVT screen 66.2 sec and DRVVT confirm with phospholipid 37 sec; ratio 66.2/37 = 1.79 (>1.15).

Revised Sapporo (Sydney) classification: II. Clinical criteria

  • ≥1 vascular thrombosis: ≥1 clinical episode of arterial, venous, or small-vessel thrombosis.
  • Pregnancy morbidity:
    • ≥1 unexplained loss of a morphologically normal fetus at ≥10 weeks (by ultrasound or direct fetal exam); or
    • ≥3 unexplained consecutive spontaneous losses at <10 weeks, without maternal anatomic or hormonal abnormalities and without paternal/maternal chromosomal abnormalities; or
    • ≥1 premature birth <34 weeks of a morphologically normal neonate due to eclampsia / severe preeclampsia OR placental insufficiency.

2023 ACR/EULAR APS classification criteria

  • 2023 ACR/EULAR APS classification criteria (Barbhaiya Ann Rheum Dis 2023 / Arthritis Rheumatol 2023, supersedes Sapporo/Sydney 2006 for research classification). Entry criterion: ≥1 positive aPL test within 3 y of a clinical criterion. Weighted point system across 6 clinical domains (macrovascular VTE, macrovascular arterial, microvascular, obstetric, cardiac valve, hematologic) + 2 laboratory domains (coagulation-based LA; solid-phase aCL/anti-β2GPI). Threshold ≥3 points in each of the clinical and lab domains. Higher specificity than Sapporo; explicitly weights triple-positive high titer most heavily. Non-thrombotic manifestations now formally counted: thrombocytopenia, cardiac valve disease, and microvascular features (livedo racemosa, livedoid vasculopathy, aPL nephropathy, pulmonary hemorrhage, myocardial disease, adrenal hemorrhage).

APLS is associated with

  • aPL antibodies are found in ~5% of the general population.
  • Rheumatologic overlap: ~30 to 40% of SLE patients have antiphospholipid antibodies (lupus anticoagulant specifically is less common); ~40% of APLS patients have SLE.
  • Also associated with certain drugs, infections, and cancer.
  • Annual first-thrombosis risk depends on antibody profile and persistence: asymptomatic triple-positive carriers had ~5.3% per year (Pengo 2011); low-risk single-positive carriers are lower, but risk is not bounded by rheumatic-disease status.

Management

  • aPL present but no thrombosis or pregnancy complication: aspirin for primary prevention in high-risk patients (LA-positive, double or triple positivity, or persistently high titers, with or without SLE). Some guidelines suggest aspirin even in low-risk patients (low-quality meta-analysis evidence).
  • Venous thrombosis, long-term anticoagulation:
    • Warfarin, INR goal 2.0 to 3.0 for most nonpregnant individuals. If pregnant, switch to therapeutic-dose enoxaparin.
    • Warfarin is preferred over DOACs. DOACs are less effective for recurrent thrombosis prevention, especially with a history of arterial events. Consider DOACs only in lower-risk APLS (single venous VTE and low-risk aPL profile: isolated aCL or isolated anti-β2GPI at low to medium titer) or when warfarin cannot be tolerated or target INR cannot be achieved despite adherence. Do not use DOACs in patients non-adherent to VKA.
    • Do not use DOACs in patients with recurrent thrombosis on standard-intensity VKA; instead increase the INR goal, switch to standard treatment-dose LMWH (or fondaparinux), or add an antiplatelet agent.
  • Arterial thrombosis, long-term anticoagulation:
    • Standard-intensity warfarin (INR 2.0 to 3.0) or higher-intensity warfarin (INR 3.0 to 4.0), chosen by bleeding vs recurrence risk; standard-intensity warfarin plus low-dose aspirin may also be considered (EULAR 2019).
    • If recurrent arterial thrombosis despite VKA adherence, increase INR to 3.0 to 4.0, add low-dose aspirin, or switch to LMWH. DOACs are not recommended.
  • Duration: lifelong if unprovoked; discontinuation can be considered rarely, especially with low-titer aPL.
APS anticoagulation trials: warfarin vs rivaroxaban
TrialPopulation / comparisonResult
TRAPS120 patients, thrombotic APLS with triple aPL positivity; warfarin vs rivaroxaban.
  • Stopped early at 1.5 y for excess composite thromboembolic events, major bleeding, and vascular death with rivaroxaban (3% warfarin vs 19% rivaroxaban)
  • Thromboembolic events 12% rivaroxaban (4 ischemic strokes, 3 MIs) vs none with warfarin; major bleeding 7% vs 3%
Ordi-Ros RCT (Ann Intern Med 2019)190 patients with thrombotic APLS; warfarin vs rivaroxaban.
  • Recurrent thrombosis 6.3% vs 11.6% (RR 1.83; 0.71 to 4.76)
  • Recurrences with rivaroxaban predominantly arterial, recurrent stroke 0% vs 10%
  • Major bleeding similar
RAPSWarfarin vs rivaroxaban (surrogate endpoint).Endogenous thrombin potential did not meet the non-inferiority threshold vs warfarin.

Treatment framework, post-2023 criteria

Scenario-to-treatment map for antiphospholipid syndrome covering aPL carriers, venous and arterial thrombosis, recurrence on warfarin, pregnancy and catastrophic APS, with trial cards for TRAPS, ASTRO-APS and RAPS.
APS treatment by scenario (TRAPS; ASTRO-APS; RAPS; EULAR 2019). Tap to enlarge.
  • Triple-positive APS with prior thrombosis, warfarin INR 2 to 3 (DOACs inferior: TRAPS halted early for excess arterial thrombosis with rivaroxaban; RAPS failed surrogate non-inferiority; ASTRO-APS stopped early for excess strokes with apixaban, 6/23 vs 0/25). Single-/double-positive after unprovoked VTE, DOAC may be considered in selected patients, mainly if VKA is not tolerated or target INR cannot be achieved; never triple-positive or arterial (EULAR 2019, ISTH 2020 guidance). Obstetric APS, low-dose aspirin + prophylactic LMWH. Catastrophic APS (CAPS), anticoagulation + steroids + PEX/IVIG ± rituximab ± eculizumab; 2024 CAPS registry mortality still ~35% to 40%.

Monitoring anticoagulation

  • If baseline PT is prolonged (rare), use an alternative thromboplastin reagent (a combination of thromboplastins, or one demonstrated to be insensitive to the patient's aPL or LA).
  • If baseline aPTT is prolonged by the LA (common) and the patient needs a heparin drip, use an anti-Xa nomogram.

Other clinical manifestations

Body map of antiphospholipid syndrome manifestations by organ: brain, eye, heart (Libman-Sacks NBTE), adrenal, kidney, skin and blood (thrombocytopenia), with valve disease, livedo racemosa, livedoid vasculopathy, aPL nephropathy, adrenal hemorrhage and thrombocytopenia highlighted as features outside the 2006 Sydney criteria that the 2023 ACR/EULAR criteria now count, and a box listing the four criteria for definite catastrophic APS.
APS manifestations organ by organ, and when multi-organ involvement means catastrophic APS. Tap to enlarge.
  • Cardiac: nonbacterial thrombotic endocarditis (NBTE; Libman-Sacks valve vegetations); anticoagulate (VKA favored in thrombotic APS) after weighing embolic and bleeding risk. Adding aspirin needs an individual indication; incidental valve disease without thromboembolism does not mandate combined therapy.
  • CNS: in addition to stroke, nonspecific white matter lesions on MRI.
  • Kidney: aPL nephropathy, thrombosis of arteriovenous grafts in hemodialysis patients, and thrombosis after kidney transplant.
  • Thrombocytopenia: ITP, TTP, drug-induced, and HIT.
  • Skin: splinter hemorrhages, livedo reticularis and racemosa, cutaneous necrosis and infarction, digital gangrene, skin ulcerations, pseudovasculitic nodules/macules, and livedoid vasculopathy.
  • Eye: amaurosis fugax, retinal venous and arterial occlusion, and anterior ischemic optic neuropathy.
  • Adrenal insufficiency: from bilateral adrenal vein thrombosis with hemorrhagic infarction.

Coagulopathy in APLS and mixing-study patterns

Mixing-study flow (prolonged aPTT, 1:1 mix, correction means factor deficiency, failure means inhibitor, excess phospholipid shortening means lupus anticoagulant) with two APS cases: anti-prothrombin antibody and acquired FVIII inhibitor.
Mixing-study logic in APS and the two bleeding patterns to recognize. Tap to enlarge.
  • Patients with a lupus inhibitor (APLS) are at NO increased risk of bleeding. Rarely, they can carry an anti-FII (anti-prothrombin) antibody that does not block prothrombin but increases its clearance, lowering prothrombin levels.
  • Acquired FII (prothrombin) deficiency with APLS (PT and aPTT both prolonged, but only PT corrects): prolonged PT (e.g., 22 sec) and prolonged aPTT (e.g., 80 sec); PT mix corrects (e.g., 15 sec, a factor deficiency, PT covers FVII, FX, FV, FII, FI); aPTT mix stays prolonged (e.g., 55 sec, an inhibitor, the lupus inhibitor). The low prothrombin reflects ↑↑↑ clearance by the anti-FII antibody, so PT corrects with mixing.
  • Acquired FVIII deficiency with APLS: normal PT; prolonged aPTT (e.g., 90 sec) with prolonged aPTT mix (e.g., 63 sec), so an inhibitor is present; FVIII <1% with Bethesda titer 45, a FVIII inhibitor. A prolonged DRVVT (e.g., 68 sec) with prolonged DRVVT mix (e.g., 55 sec) cannot be due to the FVIII inhibitor, because Russell viper venom activates FX directly (bypassing the VIIIa/IXa complex), so FVIII deficiency or inhibitors do not affect the DRVVT; another inhibitor (LA) must be invoked.

Catastrophic APS (CAPS)

  • Occurs in <1% of APLS patients.
  • Diagnostic criteria:
    • Involvement of ≥3 organs, systems, and/or tissues.
    • Manifestations developing simultaneously or in <1 week.
    • Histopathology confirming small-vessel occlusion in at least one organ or tissue.
    • Laboratory confirmation of antiphospholipid antibodies (LA, aCL, anti-β2GPI).
  • Classification: definite CAPS requires all four criteria; probable CAPS = all four criteria except only 2 organs involved; or an early-death exception preventing repeat aPL confirmation in a previously untested patient; or criteria 1, 2, and 4 (no histology); or criteria 1, 3, and 4 with a third event 1 week to 1 month apart despite anticoagulation. Mortality ~35% to 40% (37% of episodes in the CAPS registry).
  • Treatment:
    • Anticoagulation (heparin drip, then bridge to warfarin once stable).
    • Pulse-dose steroids (methylprednisolone 0.5 to 1 g/day IV for 3 days, then prednisone 1 mg/kg).
    • IVIG 400 mg/kg per day for 5 days.
    • Plasma exchange for 5 days (can reduce aCL IgG and IgM by 95%).
    • If resistant, rituximab or eculizumab (anti-C5) off label.
  • Complement link: complement is required for aPL-mediated thrombosis in animal models, and aPL activate complement. In CAPS, 85.7% show complement activation on a functional (modified Ham) assay and 60% (6/10) have rare germline variants in complement genes; eculizumab has been used successfully, but a clinical trial is needed.

High yield

  • Need clinical event (thrombosis or pregnancy morbidity) PLUS persistent aPL on 2 occasions ≥12 weeks apart; aPL alone is not APS.
  • LA prolongs aPTT in vitro but causes thrombosis in vivo; confirm phospholipid dependence using the assay's own validated cutoff (generally 99th percentile); the dRVVT uses a normalized ratio = (patient/normal screen) / (patient/normal confirm), the values shown being illustrative.
  • Triple-positive APS = warfarin INR 2 to 3; DOACs inferior (TRAPS).
  • Pregnant APS, switch warfarin to therapeutic enoxaparin; obstetric APS, low-dose aspirin + prophylactic LMWH.
  • Rare lupus-inhibitor patient with bleeding, look for acquired anti-FII (prothrombin) deficiency (PT corrects, aPTT does not).
  • Catastrophic APS: anticoagulation + pulse steroids + IVIG or PEX ± rituximab or eculizumab.
Veli Bakalov MD, Board Review Notes 2026

For patients

Plain-language guides on Step by Step, the free patient site from HemeOncBuddy.

Medicine guides for patients: Warfarin, Enoxaparin, Rivaroxaban, Apixaban, Rituximab, Heparin, Prednisone